Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Multiple Ascending Subcutaneous Doses of Efavaleukin Alfa in Subjects With Systemic Lupus Erythematosus

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Multiple Ascending Subcutaneous Doses of Efavaleukin Alfa in Subjects With Systemic Lupus Erythematosus

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efavaleukin alfa (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Sponsors Amgen

    • Most Recent Events

    • 03 Jun 2023 Results assessing Regulatory T Cell Defects in Sle and Therapy with a Novel Il-2 Mutein presented at the 24th Annual Congress of the European League Against Rheumatism
    • 14 Nov 2022 Results comparing Treg functional phenotypes in healthy controls (phase 1a baseline) to SLE patients (at baseline and post-treatment) enrolled in a phase 1b study of efavaleukin alfa to characterize Treg defects in SLE and the effects of IL-2-targeted therapy with efavaleukin alfa on Treg expansion, presented at the ACR Convergence 2022.
    • 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top